Cargando…
Gemcitabine-Induced Hemolytic Uremic Syndrome in Lung Cancer: A Case Report
Gemcitabine is a broad-spectrum anti-metabolite drug that is widely used in the therapy of numerous advanced cancers such as pancreatic, breast, ovary, lung, and bladder cancer. Gemcitabine has been reported to cause hemolytic uremic syndrome (HUS), but the underlying mechanism is not elucidated. Th...
Autores principales: | Ahlawat, Prashant, Gupta, Monica, Upadhyay, Prateek, Gupta, Shivani, Kaur, Amanjot |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812056/ https://www.ncbi.nlm.nih.gov/pubmed/35145816 http://dx.doi.org/10.7759/cureus.20926 |
Ejemplares similares
-
Atypical Hemolytic Uremic Syndrome: A Case Report
por: Mohammed, Sohaib K, et al.
Publicado: (2019) -
Atypical Hemolytic Uremic Syndrome: Cancer-Induced or Chemotherapy-Induced?
por: Sethi, Ashish, et al.
Publicado: (2021) -
Gemcitabine induced hemolytic uremic syndrome
por: Sadjadi, Seyed-Ali, et al.
Publicado: (2012) -
Atypical Hemolytic Uremic Syndrome Secondary to Pancreatitis: A Case Report
por: Kajiyama, Tsubasa, et al.
Publicado: (2023) -
Rare Presentation of Atypical Hemolytic Uremic Syndrome in an Adult
por: Alhabhbeh, Ammar, et al.
Publicado: (2021)